en
Scientific article
Open access
English

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies

Published inLeukemia research, vol. 37, no. 9, p. 1100-1106
Publication date2013
Abstract

A phase I dose-escalation study of MSC1992371A, an oral aurora kinase inhibitor, was carried out in patients with hematologic malignancies. Patients received escalating doses either on days 1-3 and 8-10 (n=36) or on days 1-6 (n=39) of a 21-day cycle. The maximum tolerated doses were 37 and 28 mg/m(2)/day, respectively. Dose-limiting toxicities included severe neutropenia with infection and sepsis, mucositis/stomatitis, and diarrhea. Complete responses occurred in 3 patients. Four disease-specific expansion cohorts then received the dose and schedule dictated by the escalation phase but the study was prematurely discontinued due to hematologic and gastrointestinal toxicity at clinically effective doses.

Keywords
  • Administration, Oral
  • Adult
  • Aged
  • Aged, 80 and over
  • Dose-Response Relationship, Drug
  • Female
  • Follow-Up Studies
  • Hematologic Neoplasms/drug therapy/enzymology
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Prognosis
  • Protein Kinase Inhibitors/pharmacokinetics/therapeutic use
  • Remission Induction
  • Tissue Distribution
Citation (ISO format)
GRAUX, Carlos et al. A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. In: Leukemia research, 2013, vol. 37, n° 9, p. 1100–1106. doi: 10.1016/j.leukres.2013.04.025
Main files (1)
Article (Published version)
accessLevelPublic
Identifiers
ISSN of the journal0145-2126
617views
410downloads

Technical informations

Creation05/31/2014 5:52:00 PM
First validation05/31/2014 5:52:00 PM
Update time03/14/2023 9:17:36 PM
Status update03/14/2023 9:17:35 PM
Last indexation01/16/2024 10:49:31 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack